APG Asset Management N.V. decreased its holdings in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 50.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,600 shares of the medical equipment provider’s stock after selling 3,600 shares during the period. APG Asset Management N.V.’s holdings in ABIOMED were worth $823,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in ABMD. Baillie Gifford & Co. grew its stake in shares of ABIOMED by 105.2% in the 2nd quarter. Baillie Gifford & Co. now owns 2,219,136 shares of the medical equipment provider’s stock worth $578,063,000 after acquiring an additional 1,137,705 shares in the last quarter. William Blair Investment Management LLC grew its stake in shares of ABIOMED by 338.3% in the 2nd quarter. William Blair Investment Management LLC now owns 815,524 shares of the medical equipment provider’s stock worth $212,436,000 after acquiring an additional 629,455 shares in the last quarter. Amundi Pioneer Asset Management Inc. grew its stake in shares of ABIOMED by 314.3% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 648,206 shares of the medical equipment provider’s stock worth $185,120,000 after acquiring an additional 491,750 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of ABIOMED by 18.0% in the 2nd quarter. Renaissance Technologies LLC now owns 2,431,723 shares of the medical equipment provider’s stock worth $633,440,000 after acquiring an additional 370,800 shares in the last quarter. Finally, Thoroughbred Financial Services LLC grew its position in ABIOMED by 22,790.2% during the second quarter. Thoroughbred Financial Services LLC now owns 260,490 shares of the medical equipment provider’s stock valued at $26,049,000 after buying an additional 259,352 shares during the period. Hedge funds and other institutional investors own 91.10% of the company’s stock.
Shares of ABMD opened at $175.89 on Friday. ABIOMED, Inc. has a 1-year low of $174.44 and a 1-year high of $459.75. The firm’s 50 day simple moving average is $189.86 and its 200 day simple moving average is $249.56. The company has a market capitalization of $7.98 billion, a P/E ratio of 48.86, a P/E/G ratio of 1.61 and a beta of 0.45.
ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings results on Thursday, August 1st. The medical equipment provider reported $1.00 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.01. ABIOMED had a net margin of 32.35% and a return on equity of 19.84%. The business had revenue of $207.70 million for the quarter, compared to analysts’ expectations of $210.96 million. During the same period last year, the business earned $1.95 earnings per share. The business’s quarterly revenue was up 15.4% on a year-over-year basis. As a group, research analysts anticipate that ABIOMED, Inc. will post 4.28 EPS for the current year.
In other news, COO David M. Weber sold 8,095 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $206.26, for a total value of $1,669,674.70. Following the transaction, the chief operating officer now owns 132,913 shares in the company, valued at $27,414,635.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.40% of the stock is owned by company insiders.
Several equities analysts recently weighed in on the stock. Morgan Stanley lowered shares of ABIOMED from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $325.00 to $215.00 in a research report on Thursday, August 1st. William Blair reiterated a “buy” rating on shares of ABIOMED in a research report on Friday, August 2nd. Guggenheim lowered shares of ABIOMED from a “buy” rating to a “neutral” rating in a research report on Friday, August 2nd. BidaskClub lowered shares of ABIOMED from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 31st. Finally, BTIG Research downgraded shares of ABIOMED from a “buy” rating to a “neutral” rating in a report on Thursday, August 1st. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $316.50.
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
Further Reading: Stock Selection – What is cash flow?
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.